Lumos Pharma Receives Wellcome Trust Award for Advancing Potental Treatment of Creatine Transporter Deficiency (CTD)

AUSTIN, Texas – May 4th, 2015 – Lumos Pharma, Inc. (Austin, Texas) announced today that it has received an award of up to $5.5 million from the Translation Fund of the Wellcome Trust. CEO of Lumos Pharma, Richard Hawkins, stated “We are very pleased Wellcome Trust has selected Lumos for an award and we are privileged...Read More